These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 27302362)

  • 1. Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
    de la Torre R; de Sola S; Hernandez G; Farré M; Pujol J; Rodriguez J; Espadaler JM; Langohr K; Cuenca-Royo A; Principe A; Xicota L; Janel N; Catuara-Solarz S; Sanchez-Benavides G; Bléhaut H; Dueñas-Espín I; Del Hoyo L; Benejam B; Blanco-Hinojo L; Videla S; Fitó M; Delabar JM; Dierssen M;
    Lancet Neurol; 2016 Jul; 15(8):801-810. PubMed ID: 27302362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial.
    Hanney M; Prasher V; Williams N; Jones EL; Aarsland D; Corbett A; Lawrence D; Yu LM; Tyrer S; Francis PT; Johnson T; Bullock R; Ballard C;
    Lancet; 2012 Feb; 379(9815):528-36. PubMed ID: 22236802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.
    de la Torre R; de Sola S; Farré M; Xicota L; Cuenca-Royo A; Rodriguez J; León A; Langohr K; Gomis-González M; Hernandez G; Esteba S; Del Hoyo L; Sánchez-Gutiérrez J; Cortés MJ; Ozaita A; Espadaler JM; Novell R; Martínez-Leal R; Milá M; Dierssen M;
    Clin Nutr; 2020 Feb; 39(2):378-387. PubMed ID: 30962103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
    Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
    Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
    Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
    J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and tolerability of memantine for cognitive and adaptive outcome measures in adolescents and young adults with Down syndrome: a randomised, double-blind, placebo-controlled phase 2 trial.
    Costa ACS; Brandão AC; Boada R; Barrionuevo VL; Taylor HG; Roth E; Stasko MR; Johnson MW; Assir FF; Roberto MP; Salmona P; Abreu-Silveira G; Bederman I; Prendergast E; Hüls A; Abrishamcar S; Mustacchi Z; Scheidemantel T; Roizen NJ; Ruedrich S
    Lancet Neurol; 2022 Jan; 21(1):31-41. PubMed ID: 34942135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.
    Levin J; Maaß S; Schuberth M; Giese A; Oertel WH; Poewe W; Trenkwalder C; Wenning GK; Mansmann U; Südmeyer M; Eggert K; Mollenhauer B; Lipp A; Löhle M; Classen J; Münchau A; Kassubek J; Gandor F; Berg D; Egert-Schwender S; Eberhardt C; Paul F; Bötzel K; Ertl-Wagner B; Huppertz HJ; Ricard I; Höglinger GU;
    Lancet Neurol; 2019 Aug; 18(8):724-735. PubMed ID: 31278067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial.
    Huang G; Wharton W; Bhasin S; Harman SM; Pencina KM; Tsitouras P; Li Z; Hally KA; Asthana S; Storer TW; Basaria S
    Lancet Diabetes Endocrinol; 2016 Aug; 4(8):657-665. PubMed ID: 27377542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.
    Ngandu T; Lehtisalo J; Solomon A; Levälahti E; Ahtiluoto S; Antikainen R; Bäckman L; Hänninen T; Jula A; Laatikainen T; Lindström J; Mangialasche F; Paajanen T; Pajala S; Peltonen M; Rauramaa R; Stigsdotter-Neely A; Strandberg T; Tuomilehto J; Soininen H; Kivipelto M
    Lancet; 2015 Jun; 385(9984):2255-63. PubMed ID: 25771249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
    De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
    Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
    Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
    Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive executive function in Down's syndrome.
    Rowe J; Lavender A; Turk V
    Br J Clin Psychol; 2006 Mar; 45(Pt 1):5-17. PubMed ID: 16480563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial.
    Mielgo-Ayuso J; Barrenechea L; Alcorta P; Larrarte E; Margareto J; Labayen I
    Br J Nutr; 2014 Apr; 111(7):1263-71. PubMed ID: 24299662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study).
    Cieuta-Walti C; Cuenca-Royo A; Langohr K; Rakic C; López-Vílchez MÁ; Lirio J; González-Lamuño Leguina D; González TB; García JG; Roure MR; Aldea-Perona A; Forcano L; Gomis-Gonzalez M; Cés SV; Lacaille F; Ravel A; Mircher C; Walti H; Janel N; Dairou J; Lévy M; Durand S; Dierssen M; Sacco S; Fornell RT;
    Genet Med; 2022 Oct; 24(10):2004-2013. PubMed ID: 35951014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.
    van der Vaart T; Plasschaert E; Rietman AB; Renard M; Oostenbrink R; Vogels A; de Wit MC; Descheemaeker MJ; Vergouwe Y; Catsman-Berrevoets CE; Legius E; Elgersma Y; Moll HA
    Lancet Neurol; 2013 Nov; 12(11):1076-83. PubMed ID: 24090588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
    Chan D; Binks S; Nicholas JM; Frost C; Cardoso MJ; Ourselin S; Wilkie D; Nicholas R; Chataway J
    Lancet Neurol; 2017 Aug; 16(8):591-600. PubMed ID: 28600189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin versus placebo for delirium in intensive care and subsequent cognitive impairment in patients with sepsis-associated acute respiratory distress syndrome: an ancillary study to a randomised controlled trial.
    Needham DM; Colantuoni E; Dinglas VD; Hough CL; Wozniak AW; Jackson JC; Morris PE; Mendez-Tellez PA; Ely EW; Hopkins RO
    Lancet Respir Med; 2016 Mar; 4(3):203-12. PubMed ID: 26832963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
    Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.